HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with...
Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with...
Hyundai Motor Group Accelerates AI Transformation Across Its Business, Advancing Toward the Physical AI Era
Hyundai Motor Group presents its Digital Transformation (DX) and AI transformation (AX) journey, key achievements and future vision, highlighting its preparation for the AI era and innovation across business functions Establishes the foundation for...